Literature DB >> 31062423

miR-202-5p protects rat against myocardial ischemia reperfusion injury by downregulating the expression of Trpv2 to attenuate the Ca 2+ overload in cardiomyocytes.

Yanbing Li1, Qiang Li1, Ou Zhang2, Xiaonan Guan1, Yajun Xue2, Siyuan Li3, Xianjing Zhuang3, Boda Zhou2, Guobin Miao2.   

Abstract

BACKGROUND: This study was aimed to unveil micro RNA (miRNA) expression profiles in myocardial ischemia-reperfusion (MI/R) rats and explore whether and how dysregulated miRNAs were involved in the initiation and progression of MI/R in a calcium-dependent manner. METHOD AND
RESULTS: Rat model of MI/R was established and cardiomyocytes isolated from neonatal rats cardiomyocytes were induced. Both miRNA and messenger RNA expression profiles were analyzed by Microarray. Quantitative reverse-transcription polymerase chain reaction, immunoblotting, bioinformatics analysis, dual-luciferase reporter gene assay, hematoxylin and eosin, Evans blue, and triphenyl tetrazolium chloride were also used in this study. Serum concentrations of myocardial enzymes (phosphocreatine kinase [CK], creatine kinase [CK-MB], lactate dehydrogenase [LDH]), cardiomyocytes loadage of Ca2+ , as well as the expression level of inositol 1,4,5-trisphosphate receptors (IP3R) and sarcoplasmic reticulum Ca2+ -ATPase 2a (SERCA2a) were measured, respectively. Effects of upregulation or downregulation of miR-202-5p or Trpv2 on these indicators were investigated in vivo and in vitro. In MI/R rats and hypoxia/reoxygenation-induced NCMs, miR-202-5p was downregulated, while Trpv2 was upregulated. Trpv2 was a promising target of miR-202-5p and negatively regulated by miR-202-5p. Upregulation of miR-202-5p or downregulation of Trpv2 significantly reduced the serum concentration of myocardial enzymes, as well as cardiomyocyte-produced reactive oxygen species, but inhibition of miR-202-5p or overexpression of Trpv2 brought the worsening situation for these indicators. Besides, upregulation of miR-202-5p upregulation or downregulation of Trpv2 also inhibited Ca2+ overload in cardiomyocytes, accompanied with the increase of SERCA2a and suppression of IP3R. The reduced damage degree and infarct size in myocardial tissue were contrarily worsened by miR-202-5p inhibitor.
CONCLUSION: Overexpression of miR-202-5p or downregulation of its downstream Trpv2 presented the cardioprotective effects to MI/R rats.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  Ca2+ overload; Trpv; miR-202-5p; myocardial ischemia/reperfusion

Mesh:

Substances:

Year:  2019        PMID: 31062423     DOI: 10.1002/jcb.28641

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  5 in total

1.  Mechanism of total glucosides of paeony in hypoxia/reoxygenation-induced cardiomyocyte pyroptosis.

Authors:  Xiyue Yan; Yonghua Huang
Journal:  J Bioenerg Biomembr       Date:  2021-09-28       Impact factor: 2.945

2.  Effect of miR-134 against myocardial hypoxia/reoxygenation injury by directly targeting NOS3 and regulating PI3K/Akt pathway.

Authors:  Jian-Min Xiao; Ji-Jia Wang; Li-Li Sun
Journal:  Acta Cir Bras       Date:  2019-10-14       Impact factor: 1.388

3.  Tetrandrine Ameliorates Myocardial Ischemia Reperfusion Injury through miR-202-5p/TRPV2.

Authors:  Wei Zhao; Youyang Wu; Fanhao Ye; Shiwei Huang; Hao Chen; Rui Zhou; Wenbing Jiang
Journal:  Biomed Res Int       Date:  2021-03-08       Impact factor: 3.411

4.  miR-454-3p and miR-194-5p targeting cardiac sarcolemma ion exchange transcripts are potential noninvasive diagnostic biomarkers for childhood dilated cardiomyopathy in Egyptian patients.

Authors:  Alaaeldin G Fayez; Nora N Esmaiel; Sohair M Salem; Engy A Ashaat; Sonia A El-Saiedi; Mona O El Ruby
Journal:  Egypt Heart J       Date:  2022-09-08

Review 5.  Cell type-specific microRNA therapies for myocardial infarction.

Authors:  Bohao Liu; Bryan Wang; Xiaokan Zhang; Roberta Lock; Trevor Nash; Gordana Vunjak-Novakovic
Journal:  Sci Transl Med       Date:  2021-02-10       Impact factor: 17.956

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.